Basel, October 28, 2014 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis delivered a very strong third quarter. We delivered solid sales growth with margin expansion. At the same time, we reached key innovation milestones, particularly with LCZ696 in heart failure and AIN457 in psoriasis, underlining the innovation power of the company.”
- Net sales up 4% (+5% cc)1 in Q3, with operating margin increase across Q3 and 9M
- Net sales of USD 14.7 billion grew 4% (+5% cc2) in Q3
- Strong …